8月 2026
Arcellx截至 8月 2026 的總收入為 15M - 25M
Arcellx 熱門網域產生的總收入
Arcellx 熱門網域 3 年內的總收入
Arcellx 熱門網域的總收入
Arcellx的熱門網域總造訪量
了解Arcellx市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Arcellx的熱門網域平均造訪時長
分析Arcellx參與度指標。
過去 3 個月平均造訪時長
子公司細目
Arcellx的熱門網域平均頁面瀏覽量
了解Arcellx如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Arcellx
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Choi leaves Arcellx as Vice President, CMC.Dr. Choi joins Oryon from Arcellx, now a wholly owned subsidiary of Gilead, where he served as Vice President, CMC, leading process development, CMC program management and external manufacturing sciences.
8月 27, 2026閱讀更多
新聞Arcellx decreased headcount by 108 on Jun 30th '26.Most affected staff worked at Arcellx's headquarters in Redwood City, California, where 108 people were let go effective June 30.
8月 20, 2026閱讀更多
新聞Arcellx is developing anitocel, a CAR-T cell therapy in clinical trials for relapsed or refractory multiple myeloma on Jul 1st '26.Gilead closed three acquisitions during the period: Arcellx, which is developing anitocel, a CAR-T cell therapy in clinical trials for relapsed or refractory multiple myeloma; Tubulis, which contributes an antibody-drug conjugate platform for targeted oncology applications; and Oral Medicines, a company focused on autoimmune treatments delivered via oral formulations.
7月 28, 2026閱讀更多
查看所有Arcellx信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
